Loading...
Loading...
Eli Lilly and Company
LLY
today announced it has acquired two investigational positron emission
tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers
are intended to image tau (or neurofibrillary) tangles in the brain, one of
two known hallmarks of Alzheimer's disease. Based on studies of samples
obtained at autopsy, the amount and location of tau tangles in an Alzheimer's
disease patient's brain is thought to correlate with the severity of the
disease. There are currently no approved diagnostics to detect tau tangles in
living patients, creating challenges for scientists working to understand the
progression of the disease and how therapies may impact it.
Lilly will initially focus on incorporating this new technology into its
anti-amyloid and anti-tau research and development (R&D) programs. Use of a
tau tangle tracer could enable tailoring and early identification of at-risk
patients, as well as potentially provide a marker for treatment response.
Lilly also has the option to commercialize the tracers. The tracers will be
developed and validated by a team at Avid Radiopharmaceuticals, Lilly's wholly
owned subsidiary focused on molecular imaging. Financial terms of the deal are
not being disclosed.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in